Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers

Seminars in Oncology

Volumn 29, Issue 1 SUPPL. 2, 2002, Pages 10-24

  Reed, John C ^a   Kitada, Shinichi ^a   Kim, Youngsoo ^a   Byrd, John ^b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CELL NUCLEUS RECEPTOR; GRANZYME B; INHIBITOR OF APOPTOSIS PROTEIN; MONOCLONAL ANTIBODY; PROTEIN KINASE; RITUXIMAB; STEROID RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; B LYMPHOCYTE; CELL CYCLE G0 PHASE; CELL DEATH; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONFERENCE PAPER; ENZYME ACTIVATION; HUMAN; IMMUNE RESPONSE; MODULATION; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0036175547     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.30155     Document Type: Conference Paper

References (171)

1. Apoptosis: An overview
2. Dysregulation of apoptosis in cancer
3. B-cell chronic lymphocytic leukemia: Present status and future directions
4. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia
5. B-chronic lymphocytic leukemia: A malignancy of anti-self B cells
6. Chronic lymphocytic leukemia
7. Antigen-driven selection of virgin and memory B cells
8. Molecular biology of chronic lymphocytic leukemia: Implications for therapy
9. Programmed cell death in Caenorhabditis elegans
10. Human ICE/CED-3 protease nomenclature
11. Caspases: Intracellular signaling by proteolysis
12. Mitochondria and apoptosis
13. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme
14. Mechanisms of apoptosis
15. Role of CED-4 in the activation of CED-3
16. Caenorhabditis elegans CED-4 stimulates CED-3 processing and CED-3-induced apoptosis
17. Essential role of CED-4 oligomerization in CED-3 activation and apoptosis
18. Caspase activation: The induced-proximity model
19. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3
20. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
21. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c
22. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked
23. The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis
24. Apaf1 is required for mitochondrial pathways of apoptosis and brain development
25. Apaf1 (CED-4 homolog) regulates programmed cell death in mammalian development
26. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition
27. Induction of an apoptotic program in cell-free extracts by 2-chloro-2′-deoxyadenosine 5′-triphosphate and cytochrome c
28. Interaction between the C. elegans cell-death regulators CED-9 and CED-4
29. Interaction of CED-4 with CED-3 and CED-9: A molecular framework for cell death
30. Interaction and regulation of subcellular localization of CED-4 by CED-9
31. Bcl-2 and the regulation of programmed cell death
32. The proto-oncogene Bcl-2 and its role in regulating apoptosis
33. L, and Apaf-1 form a ternary complex
34. Bcl-2 family proteins as ion-channels
35. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c
36. Bax directly induces release of cytochrome c from isolated mitochondria
37. The C. elegans protein EGL-1 is required for programmed cell death and interacts with the Bcl-2-1ike protein CED-9
38. Caenorhabditis elegans ECL-1 disrupts the interaction of CED-9 with CED-4 and promotes CED-3 activation
39. Bcl-2 family proteins
40. Double identity for proteins of the Bcl-2 family
41. Bcl-2-family proteins: The role of the BH3 domain in apoptosis
42. The TRA-1a sex determination protein of C. elegans regulates sexually dimorphic cell deaths by repressing the egl-1 cell death activator gene
43. DNA damage-induced activation of p53 by the checkpoint kinase Chk2
44. PUMA, a novel proapoptotic gene, is induced by p53
45. PUMA induces the rapid apoptosis of colorectal cancer cells
46. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex
47. Drosophila pro-apoptotic Bcl-2/Bax homologue reveals evolutionary conservation of cell death mechanisms
48. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
49. γ-radiation induces upregulation of Bax protein and apoptosis in radiosensitive cells in vivo
50. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses
51. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia
52. Movement of Bax from the cytosol to mitochondria during apoptosis
53. Conformation of the Bax C-terminus regulates subcellular location and cell death
54. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c
55. Bcl-2 and B-cell neoplasia: Dysregulation of programmed cell death in cancer
56. Bcl-2 family proteins: Regulators of apoptosis and chemoresistance in hematologic malignancies
57. Bcl-2 family proteins and the hormonal control of cell life and death in normalcy and neoplasia
58. Involvement of the bcl-2 gene in human follicular lymphoma
59. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells
60. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia
61. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX
62. Bcl-2/Bax ratios in chronic lymphocytic leukemia and their correlation with in vitro apoptosis and clinical resistance
63. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome
64. Chronic lymphocytic leukemia: A disease of disregulated programmed cell death
65. Cell death induction by receptors of the TNF family: Towards a molecular understanding
66. Activation-induced apoptosis in lymphoid systems
67. The Fas death factor
68. Molecules involved in cell death and peripheral tolerance
69. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis
70. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand
71. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome
72. Antibodies to HLA class 1 alpha1 domain trigger apoptosis of CD40-activated human B lymphocytes
73. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia
74. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia
75. Downregulation of the CD95 receptor and defect CD40-mediated signal transduction in B-chronic lymphocytic leukemia cells
76. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies
77. Apoptosis. Placing death under control
78. L- and procaspase-8- associated protein in the endoplasmic reticulum
79. BAR: An apoptosis regulator at the intersection of caspase and Bcl-2 family proteins
80. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells
81. Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions
82. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas(Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells
83. On the TRAIL from p53 to apoptosis?
84. Perforin and granzymes: Crucial effector molecules in cytolytic T lymphocyte and natural killer cell-mediated cytotoxicity
85. The cytotoxic cell protease granzyme B initiates apoptosis in a cell-free system by proteolytic processing and activation of the ICE/CED-3 family protease, CPP32, via a novel two-step mechanism
86. Selective regulation of apoptosis: The cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway
87. Control of programmed cell death by the baculovirus genes p35 and iap
88. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif
89. Drosophila homologs of baculovirus inhibitor of apoptosis proteins function to block cell death
90. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy
91. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins
92. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes
93. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors
94. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
95. An emerging blueprint for apoptosis in Drosophila
96. BIRinging chromosomes through cell division - And survivin' the experience
97. X-linked IAP is a direct inhibitor of cell-death proteases
98. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases
99. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases
100. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia
101. Expression and prognostic significance of iap-family genes in human cancers and myeloid leukemias
102. Livin, a novel inhibitor of apoptosis protein family member
103. IAP family proteins - Suppressors of apoptosis
104. Survivin apoptosis: An interloper between cell death and cell proliferation in cancer
105. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
106. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
107. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
108. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
109. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
110. A decade of molecular biology of retinoic acid receptors
111. Steroid regulated programmed cell death during Drosophila metamorphosis
112. The steroid and thyroid hormone receptor superfamily
113. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation
114. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3
115. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
116. Regulation of TRAIL-induced apoptosis by transcription factors
117. TRAIL: A molecule with multiple receptors and control mechanisms
118. Death receptors: Signaling and modulation
119. Safety and antitumor activity of recombinant soluble Apo2 ligand
120. Modulation of life and death by the TNF receptor superfamily
121. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics
122. Cell death: TRAIL and its receptors
123. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
124. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
125. Inhibition of death receptor signals by cellular FLIP
126. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors
127. A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor γ
128. Prospects for prevention and treatment of cancer with SPARMs (selective PPARγ modulators)
129. PPARγ modulators reduce flip protein levels and sensitize tumor cells to TRAIL-induced apoptosis
130. Induction of latent sensitivity to Fas-mediated apoptosis of chronic lymphocytic leukemia cells by CD40-ligation may explain activity of CD154 gene therapy
131. CD95's deadly mission in the immune system
132. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
133. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts
134. Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue
135. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines
136. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl- 2 modulation or dependence on functional p53
137. Overexpression of A1, an NF-kB-inducible, anti-apoptotic Bcl gene, inhibits endothelial cell activation
138. NF-kB-mediated up-regulation of bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes
139. Nuclear factor (NF)-kB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor α-induced apoptosis
140. Cytokine induced expression of porcine inhibitor of apoptosis protein (iap) family member is regulated by NF-kB
141. IEX-1L, an apoptosis inhibitor involved in NF-kB-mediated cell survival
142. Specificities of CD40 signaling: Involvement of TRAF2 in CD40-induced NF-kB activation and intercellular adhesion molecule-1 up-regulation
143. Control of apoptosis by Rel/NF-kappaB transcription factors
144. A ubiquitin ligase complex essential for the NF-κB, Wnt/Wingless, and Hedgehog signaling pathways
145. IκB kinase: Beginning, not the end
146. NF-KB activation: The IκB kinase revealed?
147. The SCF-β-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IκBα and β-catenin and stimulates IκBα ubiquitination in vitro
148. β-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IκBα and β-catenin and stimulates IκBα ubiquitination in vitro
149. IκBα ubiquitination is catalyzed by an SCF-like complex containing Skp1, cullin-1, and two F-box/WD40-repeat proteins, βTrCP1 and βTrCP2
150. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
151. Inhibition of IκB kinase and IκB phosphorylation by 15-deoxy-delta(12,14)-prostaglandin J(2) in activated murine macrophages
152. Proteasome inhibition: A new strategy in cancer treatment
153. Proteasome inhibitors: From in vitro uses to clinical trials
154. Proteasome inhibitors as anticancer agents
155. Modulation of NF-kB activity and apoptosis in chronic lymphocytic leukemia B cells
156. Cellular survival: A play in three Akts
157. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
158. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt
159. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136
160. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor
161. Akt phosphorylates and regulates the orphan nuclear receptor Nur77
162. Regulation of cell death protease caspase-9 by phosphorylation
163. Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes
164. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation
165. The protooncogene TCL1 is an Akt kinase coactivator
166. AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide-dependent phosphorylation
167. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: Comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides
168. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma
169. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells
170. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3
171. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL